CLCM
XLRN

Crawford Lake Capital Management’s Acceleron Pharma XLRN Stock Holding History

Crawford Lake Capital Management’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-19,106
Closed -$927K – 122
2018
Q2 		$927K Buy
+19,106
New +$696K 0.16% 65

Other funds holding XLRN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Crawford Lake Capital Management's XLRN Position: Q3 2018 in Review

Crawford Lake Capital Management sold out of Acceleron Pharma (XLRN) in Q3 2018, closing a stake of 19,106 shares — an estimated $927K sold.

Crawford Lake Capital Management first reported a position in XLRN in Q2 2018 and held it in 1 quarter. The position peaked at $927K in Q2 2018. 167 funds tracked by Wall St. Rank hold XLRN as of Q3 2018.

  • Crawford Lake Capital Management reported no remaining Acceleron Pharma position as of Q3 2018 after selling out during the quarter.
  • Crawford Lake Capital Management sold 19,106 Acceleron Pharma shares in Q3 2018, an estimated $927K.
  • Crawford Lake Capital Management first reported a position in Acceleron Pharma in Q2 2018 and held it in 1 quarter.
  • Crawford Lake Capital Management's Acceleron Pharma position peaked at $927K in Q2 2018.
  • 167 funds tracked by Wall St. Rank held Acceleron Pharma as of Q3 2018.

Based on Crawford Lake Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.